Research: GONZALEZ and ISAACS

Listed in Issue 46

Abstract

GONZALEZ and ISAACS conducted a 2-year, unblinded, 1-treatment arm, 10-patient, pilot prospective case study to study the effects of proteolytic enzymes, diet, nutritional supplements and detoxification procedures to treat patients with inoperable stage II-IV pancreatic cancer .

Background

Methodology

From January 1993 to April 1996 10 patients with inoperable, biopsy-proven pancreatic adenocarcinoma were entered into the trial which took place from the authors private practice. The patients were treated with large doses of orally ingested pancreatic enzymes, nutritional supplements, detoxification procedures and an organic diet. An 11th patient was added to the study after a patient dropped out. All 11 patients are considered in the data tabulation. Patients followed the treatment at home, under the supervision of the authors.

Results

As at 12 January 1999, of the 11 patients entered into the study, 9 (81%) survived one year, 5 (45%) survived two years, and at this time 4 have survived three years. Two patients are alive and doing well: one at three years, the other at 4 years. These results are far above the 25% survival at one year and 10% survival at two years for all stages of pancreatic adenocarcinoma reported in the National Cancer Data Base from 1995.

Conclusion

The results of this pilot study suggests that an aggressive nutritional therapy with large doses of pancreatic enzymes may lead to significantly increased survival over what would normally be expected for patients with inoperable pancreatic adenocarcinoma .

References

Gonzalez NJ and Isaacs LL Evaluation of pancreatic proteolytic enzyme treatment of adenocarcinoma of the pancreas, with nutrition and detoxification support. Nutrition and Cancer 33(2): 117-24. 1999.

Comment

The above results are truly astonishing and should be read as headlines throughout the world. 81% of Gonzalez and Isaacs patients survived one year as compared to only 25% of patients who normally survive for one year, and that 45% survived 2 years, compared to merely 10% in the usual statistics! Although this is a small study, for those patients whose lives were and are being prolonged, this is highly significant. Let us now see the funds required to properly research this protocol!

ICAN 2024 Skyscraper

Scientific and Medical Network 2

Cycle Around the World for Charity 2023

Climb Mount Kilimanjaro Charity 2023

top of the page